New hepatitis C therapies with high price tags and the exploitation of loopholes for compounded medications contributed to a 13.1 percent increase in U.S. drug spending in 2014, a rate not seen in more than a decade, according to the 2014 Express Scripts Drug Trend Report.
As the Galleri test is advancing toward becoming the first multi-cancer detection test to secure FDA approval, cancer care providers are coming up with strategies for using these tests responsibly.
